174 related articles for article (PubMed ID: 23602612)
1. A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials.
Goyal N; Gomeni R
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1570-6. PubMed ID: 23602612
[TBL] [Abstract][Full Text] [Related]
2. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
[TBL] [Abstract][Full Text] [Related]
3. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.
Rabinowitz J; Davidov O
Schizophr Bull; 2008 Mar; 34(2):286-91. PubMed ID: 18212325
[TBL] [Abstract][Full Text] [Related]
4. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
[TBL] [Abstract][Full Text] [Related]
6. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
Goyal N; Gomeni R
Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
[TBL] [Abstract][Full Text] [Related]
7. A bias correction in testing treatment efficacy under informative dropout in clinical trials.
Kong F; Chen YF; Jin K
J Biopharm Stat; 2009 Nov; 19(6):980-1000. PubMed ID: 20183460
[TBL] [Abstract][Full Text] [Related]
8. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
Gomeni R; Lavergne A; Merlo-Pich E
Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
[TBL] [Abstract][Full Text] [Related]
9. An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.
Funatogawa T; Funatogawa I; Takeuchi M
Stat Med; 2008 Dec; 27(30):6351-66. PubMed ID: 18767204
[TBL] [Abstract][Full Text] [Related]
10. A joint model for nonlinear longitudinal data with informative dropout.
Hu C; Sale ME
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):83-103. PubMed ID: 12800808
[TBL] [Abstract][Full Text] [Related]
11. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
13. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.
Fleischhacker WW; Derks E; Kahn RS
Schizophr Res; 2012 Jun; 138(1):39-40. PubMed ID: 22542244
[TBL] [Abstract][Full Text] [Related]
14. Pattern mixture models and latent class models for the analysis of multivariate longitudinal data with informative dropouts.
Dantan E; Proust-Lima C; Letenneur L; Jacqmin-Gadda H
Int J Biostat; 2008; 4(1):Article 14. PubMed ID: 22462120
[TBL] [Abstract][Full Text] [Related]
15. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.
Ortega I; Perez-Ruixo JJ; Stuyckens K; Piotrovsky V; Vermeulen A
J Clin Pharmacol; 2010 Mar; 50(3):293-310. PubMed ID: 20056804
[TBL] [Abstract][Full Text] [Related]
16. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.
Lalovic B; Hutmacher M; Frame B; Miller R
J Clin Pharmacol; 2011 May; 51(5):706-18. PubMed ID: 20663989
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
Pilla Reddy V; Kozielska M; Johnson M; Mafirakureva N; Vermeulen A; Liu J; de Greef R; Rujescu D; Groothuis GM; Danhof M; Proost JH
J Clin Psychopharmacol; 2013 Dec; 33(6):731-9. PubMed ID: 24113674
[TBL] [Abstract][Full Text] [Related]
18. Performance of nonlinear mixed effects models in the presence of informative dropout.
Björnsson MA; Friberg LE; Simonsson US
AAPS J; 2015 Jan; 17(1):245-55. PubMed ID: 25421458
[TBL] [Abstract][Full Text] [Related]
19. Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts.
Ali MW; Siddiqui O
J Biopharm Stat; 2000 May; 10(2):165-81. PubMed ID: 10803723
[TBL] [Abstract][Full Text] [Related]
20. CUtLASS confirms CATIE.
Mintz J; Kopelowicz A
Arch Gen Psychiatry; 2007 Aug; 64(8):978; author reply 979-80. PubMed ID: 17679644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
